Amanda L Jackson , MD

Bachelor's Degree: Clemson University Clemson, SC, 2002

Doctoral Degree: University of South Carolina Charleston, SC, 2007

Residency: Warren Alpert Medical School at Brown University Providence, RI, 2011 (Obstetrics and Gynecology)

Fellowship: University of North Carolina Chapel Hill, NC, 2014 (Gynecologic Oncology)

American Board of Obstetrics and Gynecology (Gynecologic Oncology) (Certification Date: 04-07-2017 ) - (Recertification Date: to 12-31-2024 )

American Board of Obstetrics and Gynecology (Certification Date: 01-18-2013 ) - (Recertification Date: to 12-31-2024 )

Gynecologic Oncology

Obstetrics and Gynecology

Oncology

Adenomyosis

Adnexal Disease

Adnexal Tumors

Cervical Cancer

Dysgerminoma

Embryonal Carcinoma

Embryonal Tumors

Endometrial Cancer

Endometrial Stromal Sarcoma

Endometriosis

Fallopian Tube Cancer

Fibroids

Germ Cell and Embryona Cancers

Germ Cell Tumor

Gestational Trophoblastic Neoplasia

Human Papilloma Virus (HPV)

Krukenberg Tumor

Other Complicated Gynecologic Cancers

Ovarian Cancer

Ovarian Cyst

Pelvic Cancers

Pelvic Masses

Placenta Accreta

Precancer in the Vagina

Precancer in the Vulva

Precancers in the Cervix

Uterine Fibroids (Uterine leiomyoma)

Uterine Hemorrhage

Uterine Polyps (Endometrial Polyps)

Uterine Sarcoma

Vaginal Cancer

Vulvar Cancer

Gynecologic Oncology

Obstetrics and Gynecology

Gynecologic Oncology, Advanced Pelvic Surgery, Minimally Invasive Surgery - Robotic Surgery, Sentinel lymph node mapping using fluorescence imaging

Grant: #Duke Consortium Participation Agreement_V Foundation D2019-024 Investigators:Jackson, Amanda 07-01-2019 -07-01-2023 The V Foundation ENDOMETRIAL CANCER MOLECULARLY TARGETED THERAPY CONSORTIUM Role:PI 7500.00 Awarded Level:Non Profit

Grant: #NP-G2-044-P2-01 Investigators:Jackson, Amanda 09-01-2021 -08-31-2024 Medpace Inc. NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies Role:PI 605293.40 Hold Level:Industry

Grant: #ONC-392-001 10-01-2021 -09-30-2024 OncoC4, Inc. Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study Role:PI 490140.75 Awarded Level:Industry

Grant: #ONC-392-001 10-01-2021 -09-30-2024 OncoC4, Inc. Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study Role:PI 490140.75 Awarded Level:Industry

Grant: #MER-XMT-1536-3/GOG-3049 03-01-2022 -03-01-2025 GOG Foundation, Inc. A Phase 3, Randomized, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin as Post-Platinum Maintenance Therapy for Participants with Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) Role:PI 271962.76 Hold Level:Non Profit

Grant: #MER-XMT-1536-3/GOG-3049 03-01-2022 -03-01-2025 GOG Foundation, Inc. A Phase 3, Randomized, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin as Post-Platinum Maintenance Therapy for Participants with Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) Role:PI 271962.76 Hold Level:Non Profit

Grant: #XPORT-EC-042 Investigators:Jackson, Amanda 06-29-2023 -06-29-2026 Karyopharm Therapeutics A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL Role:PI 114078.93 Hold Level:Industry

Grant: #IMGN853-0421 Investigators:Jackson, Amanda 07-15-2023 -07-15-2026 ImmunoGen, Inc. Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRalpha-high recurrent Role:PI 275467.10 Hold Level:Industry

Grant: #STRO-002-GM3 Investigators:Jackson, Amanda 08-15-2023 -08-15-2026 GOG Foundation, Inc. A Phase 2 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (including Fallopian Tube or Prim Role:PI 150471.08 Hold Level:Non Profit

Grant: #MK-2870-005 Investigators:Jackson, Amanda 03-20-2024 -03-20-2027 Merck Sharp & Dohme LLC A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometria Role:PI 157908.57 Hold Level:Industry

Grant: #GCT1046-05 Investigators:Jackson, Amanda 10-27-2024 -11-27-2024 Genmab US, Inc SUA - Phase 2 Exploratory, Multicenter, Open-Label Trial to Determine the Safety and Preliminary Clinical Activity of GEN1046 in Combination With Anticancer Agents in Subjects With Advanced Endometria Role:PI 41940.00 Active Level:Industry

Grant: #SGR-3515-101 Investigators:Jackson, Amanda 11-27-2024 -11-27-2027 Schrodinger A FIRST-IN-HUMAN, PHASE 1, DOSE- ESCALATION STUDY OF SGR-3515 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS Role:PI 422189.63 Hold Level:Industry

Grant: #Harold & Barbara Rosenbaum Family Fdtn Cervical Cancer Grant Investigators:Butsch-Kovacic, Melinda; Jackson, Amanda; Pinder, Leeya 04-01-2025 -03-31-2026 Foundation for Women's Cancer Improving Access to Cervical Cancer Screening: HPV Self-Testing on the Hamilton County 513Relief Bus (IMPACT-513 Study) Role:Collaborator 55350.00 Hold Level:Non Profit

Grant: #MK-2870-020/GOG-3101 Investigators:Jackson, Amanda 04-30-2025 -04-30-2028 Merck Sharp & Dohme LLC A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Par Role:PI 267104.79 Hold Level:Industry

Grant: #FTH-PIK-201 05-12-2025 -05-12-2028 GOG Foundation, Inc. An Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) with Paclitaxel, and a Substudy Evaluating PIKTOR with Paclitaxel plus an Insulin-Suppressing Diet, Role:PI 320144.96 Hold Level:Non Profit

Grant: #FTH-PIK-201 05-12-2025 -05-12-2028 GOG Foundation, Inc. An Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) with Paclitaxel, and a Substudy Evaluating PIKTOR with Paclitaxel plus an Insulin-Suppressing Diet, Role:PI 320144.96 Hold Level:Non Profit

Peer Reviewed Publications

Ko E, Walter P, Clark L, Jackson A, Franasiak J, Bolac C, Havrilesky L, Alvarez Secord A, Moore D, Gehrig P, Bae-Jump V. (2014. ) The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance. Gynecol Oncol, , 133 (1 ) ,28-32

Matteson KA, Phipps MG, Raker C, Sacco LJ, Jackson AL. (2009. ) Discussion: 'Laparoscopic versus vaginal hysterectomy for benign pathology' by Candiani et al. Am J Obstet Gynecol, , 200 (4 ) ,e1-6

Ko EM, Walter P, Jackson A, Clark L, Franasiak J, Bolac C, Havrilesky LJ, Secord AA, Moore DT, Gehrig PA, Bae-Jump V. (2014. ) Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol, , 132 (2 ) ,438-442

Rossi EC, Jackson A, Ivanova A, Boggess JF. (2013. ) Detection of sentinel nodes for endometrial cancer with robotic assisted fluorescence imaging: cervical versus hysteroscopic injection. International Journal of Gynecologic Oncology, , 23 (9 ) ,1704-17011

Kilgore JE, Jackson AL, Ko EM, Soper JT, Van Le L, Gehrig PA, Boggess JF. (2013. ) Recurrence-free and 5-year survival following robotic-assisted surgical staging for endometrial carcinoma. Gynecol Oncol, , 129 (1 ) ,49-53

Van Le L, Jackson A, Schuler K, Suri A, Kilgore J, Ko E, Gehrig P, Brewster W. (2012. ) Discussion: 'Surgical staging in early ovarian carcinoma' by Garcia-Soto et al. Am J Obstet Gynecol, , 206 (3 ) ,e1-3

Van Le L, Jackson A, Schuler K, Suri A, Doll K, Stine J, Kim K. (2013. ) Discussion: 'Ovarian epithelial carcinoma with pelvic endometriosis,' by Wang et al. Am J Obstet Gynecol., , 208 (5 ) ,e1-2

Book Chapter

Van Le L, Jackson A (2012 ) Cervical Cancer-Staging and Surgical Considerations.” Management of Gynecological Cancers in Older Women. .Springer-Verlag